Zacks Small Cap Research on MSN
INAB: Introducing INB-600, A γδ T Cell Engager Platform
Following the announcement of its new γδ T cell engager platform INB-600, IN8bio, Inc. (NASDAQ:INAB) reported 2024 financial ...
IN8bio announces INB-619, a novel γδ T cell therapy platform targeting CD19, showing promise in B cell depletion with reduced side effects. IN8bio, Inc. has announced the launch of its innovative γδ T ...
NEW YORK, June 02, 2025 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta (γδ) T cell therapies for cancer and autoimmune ...
All patients treated with INB-200 who completed mandated doses to date have exceeded a progression-free survival (PFS) of seven months Most patients exceeded the expected median PFS based on age and ...
INB-100 continues to demonstrate durable complete remissions (CR) with no relapses observed in any acute myeloid leukemia (AML) patients including those with high-risk disease after a median follow-up ...
INB-200 shows significantly improved progression-free survival in glioblastoma patients, with favorable safety profile and no serious toxicities reported. Repeated doses of INB-200 demonstrated an ...
IN8bio (NASDAQ:INAB) stock rose ~110% on Monday after the company reported data from a phase 1 trial of INB-100 in patients with leukemia. The company said that data showed that 100% of evaluable ...
Patient with a grade 4, IDH-mutant, MGMT-methylated glioma remains alive and progression-free for four years after receiving treatment with the INB-200 gamma-delta T cell therapy in glioblastoma trial ...
Repeated doses of INB-200 demonstrate extended median progression-free survival (mPFS) of 16.1 months, more than double the expected 6.9 months typically observed with the standard-of-care (SOC) Stupp ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results